89BIO, INC. (ETNB): Price and Financial Metrics
ETNB Price/Volume Stats
| Current price | $8.31 | 52-week high | $22.93 |
| Prev. close | $8.25 | 52-week low | $6.57 |
| Day low | $8.19 | Volume | 97,613 |
| Day high | $8.45 | Avg. volume | 1,214,754 |
| 50-day MA | $10.97 | Dividend yield | N/A |
| 200-day MA | $11.88 | Market Cap | 791.32M |
ETNB Stock Price Chart Interactive Chart >
89BIO, INC. (ETNB) Company Bio
89bio, Inc. operates as a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of innovative therapies for nonalcoholic steatohepatitis (NASH), liver and cardio-metabolic diseases. The company was founded on January 01, 2018 and is headquartered in San Francisco, CA.
Latest ETNB News From Around the Web
Below are the latest news stories about 89BIO INC that investors may wish to consider to help them evaluate ETNB as an investment opportunity.
89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)SAN FRANCISCO, Dec. 19, 2023 (GLOBE NEWSWIRE) -- 89bio, Inc. (the “Company” or “89bio”) (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, today announced that the Compensation Committee of the Company’s Board of Directors approved the grant of non-qualified stock options to purchase an aggregate of 49,000 shares of the Company’s common stock to two new employ |
89bio, Inc.'s (NASDAQ:ETNB) one-year returns climbed after last week's 7.0% gain, institutional investors must be happyKey Insights Significantly high institutional ownership implies 89bio's stock price is sensitive to their trading... |
89bio Announces Closing of its Upsized Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional SharesSAN FRANCISCO, Dec. 12, 2023 (GLOBE NEWSWIRE) -- 89bio, Inc. (“89bio”) (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, today announced that it closed its previously announced upsized underwritten public offering of 17,567,567 shares of its common stock, including the full exercise by the underwriters of their option to purchase an additional 2,432,432 share |
89bio, Inc. Announces Upsized Pricing of $150.0 Million Public Offering of Common Stock and Pre-Funded WarrantsSAN FRANCISCO, Dec. 07, 2023 (GLOBE NEWSWIRE) -- 89bio, Inc. (“89bio”) (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, today announced the pricing of its previously announced upsized underwritten public offering of 15,135,135 shares of its common stock at a public offering price per share of $9.25 and, in lieu of common stock to a certain investor, pre-fund |
89bio, Inc. Announces Proposed Underwritten Public Offering of Common Stock and Pre-Funded WarrantsSAN FRANCISCO, Dec. 06, 2023 (GLOBE NEWSWIRE) -- 89bio, Inc. (“89bio”) (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, today announced that it has commenced an underwritten public offering of $125.0 million of shares of its common stock or, in lieu of common stock to certain investors that so choose, pre-funded warrants to purchase shares of its common stoc |
ETNB Price Returns
| 1-mo | -26.53% |
| 3-mo | -18.29% |
| 6-mo | 24.03% |
| 1-year | -45.83% |
| 3-year | -69.13% |
| 5-year | N/A |
| YTD | -25.60% |
| 2023 | -12.25% |
| 2022 | -2.60% |
| 2021 | -46.37% |
| 2020 | -7.30% |
| 2019 | N/A |
Loading social stream, please wait...